Bora Pharmaceuticals and GSK Renew Manufacturing Partnership

Bora Pharmaceuticals and GSK have signed a strategic agreement to renew their five-year manufacturing partnership, valued at $250 million. This collaboration, which extends through 2030, reinforces their long-standing relationship that began when Bora Pharmaceuticals purchased the Canada===Mississauga facility from GSK in 2020. Under the renewed agreement, Bora Pharmaceuticals will continue to manufacture over 20 commercial product lines and more than 335 individual products for GSK at its Canada===Mississauga facility, covering critical therapeutic areas such as HIV, malaria, and mental health. The partnership also expands, allowing GSK access to multiple sites within the Bora Pharmaceuticals network, including its newest oral solid dose site in United States===Maple Grove, Minnesota. This agreement highlights Bora Pharmaceuticals' strong execution in development and commercial manufacturing and ensures uninterrupted supply of critical therapies for GSK patients worldwide.